Compare DTF & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTF | NORD |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Professional Services |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 95.5M |
| IPO Year | 1995 | 2005 |
| Metric | DTF | NORD |
|---|---|---|
| Price | $11.41 | $2.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.5K | ★ 15.8K |
| Earning Date | 01-01-0001 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,346.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.14 | $2.14 |
| 52 Week High | $11.66 | $5.28 |
| Indicator | DTF | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 25.07 |
| Support Level | $11.39 | $2.14 |
| Resistance Level | $11.57 | $3.52 |
| Average True Range (ATR) | 0.08 | 0.55 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 19.35 | 22.56 |
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.